Comparison of baseline characteristics of patients who had a documented relapse and that of age and WBC at diagnosis-matched controls that remain in CRm (beyond 2 years after completion of therapy)
| Parameter . | Relapsed cases (n = 31), N (%)/median (range) . | Controls (n = 35), N (%)/median (range) . | Impact on RFS (P) . |
|---|---|---|---|
| Age, y | |||
| < 10 | 7 (22.6) | 4 (11.4) | |
| 11-15 | 3 (9.7) | 6 (17.1) | NS |
| 16-55 | 21 (67.7) | 23 (65.7) | |
| > 55 | 0 | 2 (5.7) | |
| Sex: male | 20 (64.5) | 14 (40.0) | NS |
| Hemoglobin, × 10 g/Lt | 8.3 (2.1-16.0) | 8.6 (3.7-15.5) | NS |
| WBC | |||
| < 5 × 109/Lt | 15 (48.4) | 14 (40.0) | NS |
| ≥ 5 × 109/Lt | 16 (51.6) | 21 (60.0) | |
| < 10 × 109/Lt | 18 (58.1) | 21 (60.0) | NS |
| ≥ 10 × 109/Lt | 13 (41.9) | 14 (40.0) | |
| Platelets | |||
| ≤ 20 × 109/Lt | 18 (58.1) | 23 (65.7) | NS |
| > 20 × 109/Lt | 13 (41.9) | 12 (34.3) | |
| Good-risk group* | 6 (19.4) | 8 (22.9) | NS |
| High-risk group | 25 (80.6) | 27 (77.1) | |
| RT-PCR | |||
| bcr1 | 20 (64.5) | 21 (60) | |
| bcr2 | 2 (6.5) | 4 (11.4) | NS |
| bcr3 | 9 (29.0) | 10 (28.6) | |
| Lactate dehydrogenase, IU/Lt | 527 (280-2385) | 564 (226-2200) | NS |
| Serum creatinine, mg/100 mL | 0.9 (0.5-1.2) | 0.8 (0.5-1.6) | NS |
| Additional CTG finding | |||
| Yes | 15 (60.0) | 9 (29.0) | .030 |
| No | 10 (40.0) | 22 (71.0) | |
| FLT3 mutation (ITD/TKD) | |||
| Yes | 10 (35.7) | 11 (34.4) | NS |
| No | 18 (64.3) | 21 (65.6) |
| Parameter . | Relapsed cases (n = 31), N (%)/median (range) . | Controls (n = 35), N (%)/median (range) . | Impact on RFS (P) . |
|---|---|---|---|
| Age, y | |||
| < 10 | 7 (22.6) | 4 (11.4) | |
| 11-15 | 3 (9.7) | 6 (17.1) | NS |
| 16-55 | 21 (67.7) | 23 (65.7) | |
| > 55 | 0 | 2 (5.7) | |
| Sex: male | 20 (64.5) | 14 (40.0) | NS |
| Hemoglobin, × 10 g/Lt | 8.3 (2.1-16.0) | 8.6 (3.7-15.5) | NS |
| WBC | |||
| < 5 × 109/Lt | 15 (48.4) | 14 (40.0) | NS |
| ≥ 5 × 109/Lt | 16 (51.6) | 21 (60.0) | |
| < 10 × 109/Lt | 18 (58.1) | 21 (60.0) | NS |
| ≥ 10 × 109/Lt | 13 (41.9) | 14 (40.0) | |
| Platelets | |||
| ≤ 20 × 109/Lt | 18 (58.1) | 23 (65.7) | NS |
| > 20 × 109/Lt | 13 (41.9) | 12 (34.3) | |
| Good-risk group* | 6 (19.4) | 8 (22.9) | NS |
| High-risk group | 25 (80.6) | 27 (77.1) | |
| RT-PCR | |||
| bcr1 | 20 (64.5) | 21 (60) | |
| bcr2 | 2 (6.5) | 4 (11.4) | NS |
| bcr3 | 9 (29.0) | 10 (28.6) | |
| Lactate dehydrogenase, IU/Lt | 527 (280-2385) | 564 (226-2200) | NS |
| Serum creatinine, mg/100 mL | 0.9 (0.5-1.2) | 0.8 (0.5-1.6) | NS |
| Additional CTG finding | |||
| Yes | 15 (60.0) | 9 (29.0) | .030 |
| No | 10 (40.0) | 22 (71.0) | |
| FLT3 mutation (ITD/TKD) | |||
| Yes | 10 (35.7) | 11 (34.4) | NS |
| No | 18 (64.3) | 21 (65.6) |
NS indicates not significant.
Defined as WBC < 5 × 109/Lt and platelets > 20 × 109/Lt.